Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial
Key result
ISCHEMIA trial baseline shows ~79% of stable ischemic heart disease patients have multivessel CAD.
- n=5,179
Why the study?
It was unknown whether coronary revascularization added to optimal medical therapy improves prognosis in patients with stable ischemic heart disease at increased risk due to moderate or severe ischemia.
What are the baseline characteristics and risk profiles of participants randomized in the ISCHEMIA trial?
Population
8518 enrolled and 5179 randomized SIHD patients with moderate or severe ischemia across 38 countries
Comparison
Qualification by stress imaging vs nonimaging exercise tolerance test
Design
Baseline analysis of a multinational randomized clinical trial across 341 enrolling sites
Authors
Discussion
Loading...
Member takes
Implication
Baseline profile confirms high-risk multivessel enrollment in ISCHEMIA; leaves open generalizability across sex and race subgroups.
Study Design
Type
RCT (n=5,179)
Multicenter
Yes
Structured PICO
What are the baseline characteristics and risk profiles of participants randomized in the ISCHEMIA trial?
P
Population
5,179 randomized patients with stable ischemic heart disease (SIHD) and moderate or severe ischemia on stress testing, median age 64 years, 22.6% women, multinational (38 countries).
I
Intervention
Coronary revascularization added to optimal medical therapy (trial intervention, outcomes not reported in this paper)
C
Comparator
Optimal medical therapy alone (trial comparator, outcomes not reported in this paper)
O
Outcome
Enrolled, excluded, and randomized participants' baseline characteristics
The ISCHEMIA trial successfully randomized a high-risk population of patients with stable ischemic heart disease and moderate or severe ischemia, the majority of whom had multivessel coronary artery disease.
Cite This Study
Hochman et al. (2019) conducted an RCT in Stable ischemic heart disease (SIHD) (n=5,179). Coronary revascularization vs. Optimal medical therapy was evaluated on Baseline characteristics (no clinical outcomes reported). The ISCHEMIA trial randomized 5179 patients with stable ischemic heart disease and moderate or severe ischemia, of whom 79.0% had multivessel CAD and 86.8% had left anterior descending stenosis.